Public release date: 12-Feb-2013 [ | E-mail | Share ] Contact: Catherine Afarian cat@23andme.com 408-656-8872 PeerJ A 23andMe study of consumers' reactions to genetic testing found that even when the tests revealed high-risk mutations in individuals, those individuals had few negative reactions to the news. Instead of inducing serious anxiety, the test results prompted people to take positive steps, including follow-up visits with a doctor and discussions with family members who could also be at risk. The study, titled "Dealing with the unexpected: Consumer responses to direct-access BRCA mutation testing" published today as part of the launch of PeerJ, a new peer reviewed open access journal in which all articles are freely available to everyone. "The paper addresses one of the most urgent questions in the field of genetics and genomics, namely the impact of receiving unexpected information about high genetic risk for a life-threatening disease," said the lead author of the paper and 23andMe's Senior Medical Director Dr. Uta Francke. The study looked at how people reacted when they learned for the first time that they carried a mutation in either the BRCA1 or BRCA2 gene that put them at higher risk for breast and ovarian cancer. The study … Continue reading →

Public release date: 11-Feb-2013 [ | E-mail | Share ] Contact: Vicki Bendure vicki@bendurepr.com 202-374-9259 Society for Maternal-Fetal Medicine In a study to be presented on February 14 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting , in San Francisco, researchers will report that variation in a gene involved in inflammation is associated with developmental problems after preterm birth in females, but not males. This randomized study, Sex-specific genetic susceptibility to adverse neurodevelopmental outcome after early preterm birth, may improve understanding of how developmental problems occur after preterm birth and may help identify prevention strategies. "Preterm birth is the leading cause of childhood brain injury," said the study's author, Erin Clark, MD. "Compared to preterm girls, preterm boys are more likely to die, and survivors are more likely to have long-term problems, including disability and cerebral palsy. We don't understand why preterm boys are at a disadvantage compared to girls." Through her study, Clark, assistant professor of Maternal-Fetal Medicine at the University of Utah School of Medicine, determined whether genetic variants influence the risk of developmental problems after a preterm birth, and whether there is a difference in risk factors … Continue reading →

Feb. 11, 2013 In a study to be presented on February 14 at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting , in San Francisco, researchers will report that variation in a gene involved in inflammation is associated with developmental problems after preterm birth in females, but not males. This randomized study, Sex-specific genetic susceptibility to adverse neurodevelopmental outcome after early preterm birth, may improve understanding of how developmental problems occur after preterm birth and may help identify prevention strategies. "Preterm birth is the leading cause of childhood brain injury," said the study's author, Erin Clark, MD. "Compared to preterm girls, preterm boys are more likely to die, and survivors are more likely to have long-term problems, including disability and cerebral palsy. We don't understand why preterm boys are at a disadvantage compared to girls." Through her study, Clark, assistant professor of Maternal-Fetal Medicine at the University of Utah School of Medicine, determined whether genetic variants influence the risk of developmental problems after a preterm birth, and whether there is a difference in risk factors between males and females. Clark evaluated patients previously enrolled in a randomized trial of magnesium sulfate before preterm birth for prevention of cerebral … Continue reading →

Achilles Tendon Repair (PRP and Stem Cell) Achilles tendon repair with enhancement with prp and stem cell treatment By: MiamiFootSurgery … Continue reading →

Cryo-Save: The Family Stem Cell Bank Umbilical cord blood stem cell storage is an added protection for the health of you and your family. Find out more about the workings of the Cryo-Save laboratory in Niel, Belgium and what stem cell storage means. By: CryoSaveWebmaster … Continue reading →

Public release date: 11-Feb-2013 [ | E-mail | Share ] Contact: Megan McCann memccann@nmh.org 312-926-5900 Northwestern Memorial Hospital Each year, nearly 800,000 Americans suffer a stroke which can result in permanent brain damage, long term disability or death. As a leading cause of adult disability, stroke has an annual burden of more than $62 billion on the United States economy. With the exception of rehabilitation therapy, very few treatments are available to improve the chronic neurologic deficits caused by a stroke. In hopes of expanding therapeutic options, Northwestern Medicine researchers are investigating a novel stem cell therapy, known as SB623, that may hold the key to improving motor function following a disabling stroke. Northwestern is currently one of only three sites in the nation enrolling participants in a landmark study to test the safety and efficacy of adult stem cell therapy for patients with stable ischemic stroke. Accounting for 87 percent of strokes, ischemic stroke occurs when a blocked artery interrupts the flow of oxygen and blood to the brain. This causes cell death and brain damage which can leave a person with impaired body functions, including paralysis, weakness on one side, difficulty with speech and language, vision issues, and … Continue reading →

Distinguished lecture by Prof. Ratnesh Lal Date: January 29, 2013 Venue: CV Raman Auditorium, University of Hyderabad Speaker: Prof. Ratnesh Lal, UCSD Topic: Emerging Nanoscience and Technology for Nanomedicine: Prospects and Promises About the speaker: Prof. Ratnesh Lal is a professor at University of California, San Diego (UCSD) who works in the areas of Mechanical and Aerospace Engineering, Bioengineering. A post doc from CALTECH, Prof. Lal is known for leading a multi-disciplinary team of researchers in a breakthrough discovery relating to Alzheimer's disease. In addition to seminal research publications in the field of nanomedicine, Prof. Lal holds several patents in microfluidics, optoelectronics and nanotechnology. He is also an Associate Editor of the journal Nanomedicine: Nanotechnology, Biology and Medicine. The photo documentation of the lecture can be found at: uohdistinguishedlectures.blogspot.com Copyrights@2012, University of Hyderabad. Visual Documentation by Wings and Oars Media Comm, Hyderabad, India. By: UoH DistinguishedLectures … Continue reading →

WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that its President, Dr. Anil Diwan, will present an overview of the company at the 15th Annual BIO CEO and Investor Conference. The Conference is being held at the Waldorf-Astoria Hotel in New York City (http://www.bio.org/events/conferences/15th-annual-bio-ceo-investor-conference). NanoViricides, Inc. presentation is scheduled for 11:30 am EST tomorrow, February 12th, in the Conrad Room. The first ever orally active nanomedicine has been developed by NanoViricides, Inc. This oral anti-influenza drug candidate has shown very high bioavailability. NanoViricides also has an injectable anti-influenza drug in development towards clinical studies for serious cases of influenza. A pre-IND meeting with the FDA has helped the Company build its FluCide anti-influenza therapeutics program towards human clinical trials. Both the oral and injectable anti-influenza drug candidates have shown significant superiority over oseltamivir (Tamiflu) in highly lethal animal model studies. Both drug candidates have shown strong activity against multiple, unrelated influenza types, suggesting that they indeed have broad-spectrum effectiveness against most if not all influenza viruses. NanoViricides has also shown that its drug candidates against HIV/AIDS, even while being used as a single agent, had effectiveness equivalent to a triple drug HAART cocktail therapy in … Continue reading →